Here’s what you should know.
1. Renzapride is a prokinetic agent for the gastrointestinal tract.
2. EndoLogic plans to develop the compound to treat gastroparesis.
3. Renzapride completed a phase III trial where it demonstrated a small but statistically significant benefit in constipation-dominant irritable bowel syndrome patients.
4. Alizyme halted the drug’s development because of its small impact.
5. Only metoclopramide is currently FDA-approved to treat gastroparesis, and it has severe side effects, which limits its use. If Renzapride earns FDA approval, it would be a safer alternate treatment.
More articles on gastroenterology/endoscopy:
Dr. Theresa Ruddy joins Oswego Health: 4 notes
5 most read GI/endoscopy stories — Dec. 26 to Dec. 30, 2016
GI leader to know: Dr. Michael Brody of Cary Gastroenterology Associates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
